Neppala S, Chigurupati HD, Chauhan S, Chinthapalli MT, Desai R. Impact of depression on in-hospital outcomes for adults with type 2 myocardial infarction: A United States population-based analysis. World J Cardiol 2024; 16(7): 412-421 [PMID: 39086894 DOI: 10.4330/wjc.v16.i7.412]
Corresponding Author of This Article
Shaylika Chauhan, FACP, MD, Clinical Assistant Professor (Honorary), Department of Internal Medicine, Geisinger Health System, 1000 E Mountain Blvd, Wikes-Barre, PA 18702, United States. drshaylikachauhan@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: Neppala S and Desai R contributed to the resources of this manuscript; Neppala S, Chigurupati HD, Chinthapalli MT, and Desai R participated in the writing-original draft of this article; Neppala S, Chauhan S, and Desai R were involved in the visualization; Chigurupati HD, Chauhan S, Chinthapalli MT, and Desai R took part in the writing - review & editing; Chauhan S and Desai R contributed to the conceptualization and methodology of this manuscript; Chauhan S participated in the supervision of this study; Desai R contributed to the software and formal analysis of this manuscript. All authors have read and approved the final manuscript.
Institutional review board statement: Not applicable, data is obtained from a publicly available data set, patient identifiers are not used.
Informed consent statement: Informed consent statement was not obtained from the patients as there is no patient-identifiable data included in this observational study from the National Inpatient Sample database.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available on request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shaylika Chauhan, FACP, MD, Clinical Assistant Professor (Honorary), Department of Internal Medicine, Geisinger Health System, 1000 E Mountain Blvd, Wikes-Barre, PA 18702, United States. drshaylikachauhan@gmail.com
Received: March 5, 2024 Revised: May 30, 2024 Accepted: June 25, 2024 Published online: July 26, 2024 Processing time: 140 Days and 21.9 Hours
Abstract
BACKGROUND
Type 2 myocardial infarction (T2MI) is an ischemic myocardial injury in the context of oxygen supply/demand mismatch in the absence of a primary coronary event. However, though there is a rising prevalence of depression and its potential association with type 1 myocardial infarction (T1MI), data remains non-existent to evaluate the association with T2MI.
AIM
To identify the prevalence and risk of T2MI in adults with depression and its impact on the in-hospital outcomes.
METHODS
We queried the National Inpatient Sample (2019) to identify T2MI hospitalizations using Internal Classification of Diseases-10 codes in hospitalized adults (≥ 18 years). In addition, we compared sociodemographic and comorbidities in the T2MI cohort with vs without comorbid depression. Finally, we used multivariate regression analysis to study the odds of T2MI hospitalizations with vs without depression and in-hospital outcomes (all-cause mortality, cardiogenic shock, cardiac arrest, and stroke), adjusting for confounders. Statistical significance was achieved with a P value of < 0.05.
RESULTS
There were 331145 adult T2MI hospitalizations after excluding T1MI (median age: 73 years, 52.8% male, 69.9% white); 41405 (12.5%) had depression, the remainder; 289740 did not have depression. Multivariate analysis revealed lower odds of T2MI in patients with depression vs without [adjusted odds ratio (aOR) = 0.88, 95% confidence interval (CI): 0.86-0.90, P = 0.001]. There was the equal prevalence of prior MI with any revascularization and a similar prevalence of peripheral vascular disease in the cohorts with depression vs without depression. There is a greater prevalence of stroke in patients with depression (10.1%) vs those without (8.6%). There was a slightly higher prevalence of hyperlipidemia in patients with depression vs without depression (56.5% vs 48.9%), as well as obesity (21.3% vs 17.9%). There was generally equal prevalence of hypertension and type 2 diabetes mellitus in both cohorts. There was no significant difference in elective and non-elective admissions frequency between cohorts. Patients with depression vs without depression also showed a lower risk of all-cause mortality (aOR = 0.75, 95%CI: 0.67-0.83, P = 0.001), cardiogenic shock (aOR = 0.65, 95%CI: 0.56-0.76, P = 0.001), cardiac arrest (aOR = 0.77, 95%CI: 0.67-0.89, P = 0.001) as well as stroke (aOR = 0.79, 95%CI: 0.70-0.89, P = 0.001).
CONCLUSION
This study revealed a significantly lower risk of T2MI in patients with depression compared to patients without depression by decreasing adverse in-hospital outcomes such as all-cause mortality, cardiogenic shock, cardiac arrest, and stroke in patients with depression.
Core Tip: We studied the prevalence and risk of type 2 myocardial infarction (T2MI) in adults with depression and its impact on the in-hospital outcomes which revealed a significantly lower risk of T2MI in patients with depression compared to patients without depression by decreasing adverse in-hospital outcomes. Our study revealed decreased risks of all-cause mortality, cardiogenic shock, and cardiac arrest during T2MI hospitalization in patients with depression.
Citation: Neppala S, Chigurupati HD, Chauhan S, Chinthapalli MT, Desai R. Impact of depression on in-hospital outcomes for adults with type 2 myocardial infarction: A United States population-based analysis. World J Cardiol 2024; 16(7): 412-421
Coronary heart disease (CHD) and depression have become a global health problem[1,2]. In 2020, in the United States, CHD was the leading cause of morbidity and mortality (41.2%), with approximately 382800 deaths[3]. CHD is a syndrome characterized by myocardial cell death caused by ischemia resulting from the imbalance of supply and demand[4]. Myocardial infarction has been subclassified according to pathogenesis in 2007[4]. Type 1 myocardial infarction (T1MI) is a spontaneous episode occurring due to atherothrombosis or thrombus from an atherosclerotic plaque[4,5] or in the absence of acute atherothrombosis, known as T2MI[3,4]. Although disrupted atherosclerotic thrombus has remained the hallmark cause of acute MI, multiple other mechanisms are known to cause myocardial injury. However, definitive diagnostic and therapeutic strategies are yet to be defined[4,6].
Depression is one of the most common, debilitating illnesses, affecting around 26% of women and 18% of men in the United States[7]. Depression is more common in patients with acute MI, affecting approximately 20% of patients during the hospitalization with MI and over the first year after hospitalization[8], and has been classified as a significant risk factor for poor prognosis among patients with CHD[9]. Both mental illness and CHD have been imposing a significant economic and social burden due to their higher prevalence in high- and middle-income countries[10]. Several studies in recent years have reported growing evidence of links between depression and CHD[11,12], with a higher prevalence of depression among patients following acute myocardial infarction hospitalizations ranging from 15%-32%[13,14], which is also an independent predictor of increased mortality after acute MI[14,15]. Recently, a multicenter cohort observational study (TRIUMPH trial) done by Smolderen et al[8] showed that depression in patients with acute MI has been associated with long-term mortality but is mainly confined to untreated depression. A meta-analysis done by Barth et al[16] found that depression in MI is associated with a 2.5 times higher risk of mortality. Similarly, a meta-analysis done by van Melle et al[17] and Nicholson et al[11] found an increased risk of 2.0-2.5 times poor cardiac and mortality outcomes in 2 years after an MI in depression patients.
Although the majority of CHD trials were focused mainly on the role of biological risk factors, including smoking, hyperlipidemia, obesity, hypertension, diabetes mellitus, and lifestyle, more recently, stress, anxiety, and depression have been reported as the most significant risk factors for the coronary artery disease (CAD) even after controlling biological factors[18]. However, previous research studies have several limitations concerning causal interference. Despite the increasing occurrence of depression and its potential link to T1MI, there is a lack of data to assess this relationship with T2MI. Our objective is to determine the prevalence and risk of T2MI in adults with depression, as well as to examine its influence on in-hospital outcomes.
MATERIALS AND METHODS
Design and data source
In this retrospective observational study, we analyzed the National Inpatient Sample datasets for 2019, which are available through the Healthcare Cost and Utilization Project. The National Inpatient Sample is a large publicly available database representing 95% of hospitalizations in the United States, covering 48 states and the District of Columbia. We utilized the Internal Classification of Diseases, 10th revision, Clinical Modification (ICD-10-CM) code I21.A1 to identify the principle of T2MI hospitalizations. This is an observational study looking at the prevalence and risk of T2MI in adults with depression and its impact on in-hospital outcomes. Comorbid depression was identified using these codes - F20.4, F31.3-F31.5, F32.x, F33.x, F34.1, F41.2, F43.2. Primary outcomes, including cardiovascular events, were identified using previously reported and validated ICD-10-CM codes or clinical classification software codes (The Clinical Classifications Software Refined groups ICD-10-CM/PCS codes into practical categories).
Study population and characteristics
Using the ICD-10 codes for 2019, we included hospitalized adult patients with a diagnosis of T2MI, excluding cases with T1MI.
Outcome measures
The primary outcome of this study is to assess the odds of T2MI and subsequent major adverse cardiovascular events (MACE: All-cause mortality, cardiogenic shock, cardiac arrest, and stroke) in T2MI patients with vs without comorbid depression. Secondary outcomes included health care utilization and length of hospitalization stay. We compared socio-demographic and comorbidities in the T2MI cohorts with vs without comorbid depression. Patient confounders were adjusted with multivariable regression analyses, which are known to have prognostic implications for our outcomes.
Statistical analysis
Patient characteristics and in-hospital outcomes were compared among patients with depression who were admitted with T2MI. Categorical data was displayed in percentages, and continuous data was represented using the median and interquartile range for non-normally distributed data. A P value below 0.05, determined through a two-tailed test, was deemed to show significance. National estimates were generated by leveraging the database’s discharge weight and utilizing sample modules for analysis. Odds ratios (OR) and their 95% confidence intervals (CI) were obtained using multivariable logistic regression for in-hospital mortality and outcomes. The multivariable logistic regression was adjusted for covariates such as age, gender, race, zip code-based income quartile, primary payer, and a range of comorbidities and prior conditions, including acquired immunodeficiency syndrome, alcohol and drug abuse, arthritis, hypertension (complicated and uncomplicated), diabetes (complicated and uncomplicated), hyperlipidemia, obesity, peripheral vascular disease, prior myocardial infarction with or without revascularization, tobacco use disorder, chronic lung disease, hypothyroidism, other thyroid disorders, previous MI or transient ischemic attack/stroke, and cancer. All reported P values are two-sided, with a value of < 0.05 considered significant. Statistical analyses were conducted using IBM SPSS Statistics 25.0 software (IBM Corp, Armonk, NY, United States).
RESULTS
Baseline characteristics
We identified 331145 adult T2MI hospitalizations after excluding T1MI cases. The median age was 73 years, 52.8% male and 69.9% white. Among these hospitalizations, 41405 (12.5%) had depression, leaving the remaining 289740 without depression. The T2MI+D+ cohort, in comparison with the T2MI-D- cohort, often consisted of younger (median age, 71 vs 73) females (59.9% vs 45.4%), with both cohorts predominantly including white (78.4, 68.7) (Table 1). T2MI-D+ had 4530 (11.2%), and T2MI-D- had 47880 (16.9%) black patients. The Hispanic population comprised 2490 (6.1%) in the T2MI+D+ cohort and 22790 (8.1%) in the T2MI+D- cohort. Both groups primarily had medicare-enrolled patients, 207830 (71.8%) in the T2MI-D- vs 30400 (73.5%) in T2MI+D+. Private insurance, including Health Maintenance Organization, was the next most common-36125 (12.5%) in T2MI+D- while medicaid was next most common in T2MI-D+ 4575 (11.1%).
Table 1 Demographic characteristics and comorbidities in type 2 myocardial infarction-related hospitalizations with vs without depression.
Depression
Total T2MI, n = 331145
P value
No, n = 289740
Yes, n = 41405
Age at admission
Median (IQR)
73 (62-83)
71 (61-81)
73 (62-82)
< 0.001
18-44 years
5.4%
5.0%
5.3%
45-64 years
24.1%
27.6%
24.6%
≥ 65 years
67.3%
70.1%
70.5%
Sex
< 0.001
Male
54.6%
40.1%
52.8%
Female
45.4%
59.9%
47.2%
Race
< 0.001
White
68.7%
78.4%
69.9%
Black
16.9%
11.2%
16.2%
Hispanic
8.1%
6.1%
7.8%
Asian or Pacific Islander
2.8%
1.4%
2.6%
Native American
0.8%
0.9%
0.9%
Others
2.8%
2.0%
2.7%
Median household income quartile for patient zip code
< 0.001
0-25th
32.9%
31.2%
32.7%
26-50th
26.5%
27.2%
26.6%
51-75th
23.1%
23.6%
23.2%
76-100th
17.5%
17.9%
17.5%
Primary expected payer
< 0.001
Medicare
71.8%
73.5%
72.0%
Medicaid
10.4%
11.1%
10.5%
Private including HMO
12.5%
10.8%
12.3%
Self-pay
2.9%
2.1%
2.8%
No charges
0.2%
0.1%
0.2%
Others
2.2%
2.4%
2.2%
Type of admission
0.985
Non-elective
97.0%
97.0%
97.0%
Elective
3.0%
3.0%
3.0%
Location/teaching status of hospital
< 0.001
Rural
8.4%
9.0%
8.5%
Urban non-teaching
15.6%
15.2%
15.5%
Urban teaching
76.0%
75.8%
76.0%
Region of hospital
< 0.001
Northeast
22.9%
21.7%
22.8%
Midwest
23.1%
27.9%
23.7%
South
35.0%
33.4%
34.8%
West
19.0%
17.0%
18.7%
Comorbidities
Alcohol abuse
4.9%
0.6%
5.0%
< 0.001
Arthropathies
4.1%
5.8%
4.3%
< 0.001
Dementia
10.9%
15.8%
11.6%
< 0.001
Hypertension, complicated
49.9%
49.2%
49.8%
0.006
Hypertension, uncomplicated
19.9%
22.6%
20.2%
< 0.001
Diabetes with chronic complications
31.5%
32.4%
31.6%
< 0.001
Diabetes without chronic complications
9.0%
8.9%
9.0%
0.244
Hyperlipidemia
48.9%
56.5%
49.9%
< 0.001
Obesity
17.9%
21.3%
18.4%
< 0.001
Peripheral vascular disease
11.3%
11.6%
11.3%
0.095
Prior MI
12.2%
13.2%
12.3%
< 0.001
Prior TIA/stroke
8.6%
10.1%
8.8%
< 0.001
Drug abuse
5.0%
7.4%
5.3%
< 0.001
Tobacco use disorder
15.5%
19.4%
16.0%
< 0.001
Chronic pulmonary disease
31.4%
38.9%
32.3%
< 0.001
Hypothyroidism
15.0%
21.3%
15.8%
< 0.001
Other thyroid disorders
1.5%
1.9%
1.5%
< 0.001
Anxiety & fear related disorders
9.0%
39.3%
9.0%
< 0.001
Cancer
9.3%
7.7%
9.1%
< 0.001
Elective and non-elective admissions frequency did not differ significantly between cohorts. The prevalence of prior MI with any revascularization and peripheral vascular disease was comparable among cohorts with and without depression. However, patients with depression showed a higher prevalence of stroke at 10.1% compared to those without depression at 8.6%. Additionally, patients with depression exhibited a slightly higher prevalence of hyperlipidemia (56.5% vs 48.9%) and obesity (21.3% vs 17.9%) compared to those without depression. Nonetheless, there was generally an equal prevalence of hypertension and type 2 diabetes mellitus in both cohorts.
Primary outcomes
Table 2 reveals significant differences in in-hospital outcomes for T2MI patients with versus without depression. Notably, patients with depression exhibited a lower all-cause mortality rate (5.8%) compared to those without depression (8.4%), alongside reduced incidences of cardiogenic shock, dysrhythmias, cardiac arrest, and stroke, with all differences being statistically significant (P < 0.001). After adjusting for potential confounders in a multivariable logistic regression analysis, the findings revealed that patients with depression had significantly lower odds of experiencing T2MI compared to those without depression [adjusted OR (aOR) = 0.88, 95%CI: 0.86-0.90, P = 0.001] (Table 3). Additionally, patients with depression were found to have lower risks of all-cause mortality (aOR = 0.75, 95%CI: 0.67-0.83, P = 0.001), cardiogenic shock (aOR = 0.65, 95%CI: 0.56-0.76, P = 0.001), cardiac arrest (aOR = 0.77, 95%CI: 0.67-0.89, P = 0.001), and stroke (aOR = 0.79, 95%CI: 0.70-0.89, P = 0.001) compared to patients without depression.
Table 2 In-hospital outcomes in type 2 myocardial infarction hospitalizations in patients with vs without depression.
No depression (n = 289740)
Depression (n = 41405)
Total T2MI (n = 331145)
P value
All-cause mortality
8.4%
5.8%
8.1%
< 0.001
Cardiogenic shock
3.5%
2.2%
3.4%
< 0.001
Dysrrhythmia
43.8%
40.2%
43.3%
< 0.001
Cardiac arrest including ventricular fibrillation
3.4%
2.4%
3.3%
< 0.001
Stroke
5.3%
4.1%
5.2%
< 0.001
Disposition of patient
< 0.001
Routine
39.9%
36.4%
39.5%
Transfers to short-term hospitalization
3.5%
2.9%
3.4%
Transfer other includes: Skilled nursing facility, intermediate care facility, another type of facility
27.7%
32.7%
28.3%
Home health care
19.0%
20.7%
19.2%
Length of stay (days), median (IQR)
5 (3-9)
5 (3-8)
5 (3-9)
0.243
Total charges USD, median (IQR)
53592 (29003-105279)
50156 (28249-90301)
53139 (28872-103331)
< 0.001
Table 3 Multivariable odds ratios for type 2 myocardial infarction and subsequent major adverse cardiac outcomes associated with depression.
Outcome
Predictor
Odds ratio
95% confidence interval
P value
T2MI
Depression
0.88
0.86-0.90
< 0.001
In T2MI patients
In-hospital all-cause mortality
Depression
0.75
0.67-0.83
< 0.001
Cardiogenic-shock
Depression
0.65
0.56-0.76
< 0.001
Cardiac arrest including ventricular fibrillation
Depression
0.77
0.67-0.89
0.001
Stroke
Depression
0.79
0.70-0.89
< 0.001
Secondary outcomes
For patients without depression, hospitalizations are associated with higher costs compared to patients with depression (median $53592 and $50156, respectively) without any change in length of stay with a median of 5 days. In contrast, patients with depression were most frequently transferred to skilled nursing facilities compared to patients without depression (32.7% vs 27.7%). This difference could reflect a need for more extended care or rehabilitation services in patients with depression (Table 2).
DISCUSSION
This study is one of the most extensive population-based outcome studies to explore the association between depression and the risks of T2MI, as well as its impact on incidence, demographics, and in-hospital outcomes. The study included a total of 331415 patients from the publicly available National Inpatient Sample 2019 database, of whom 41405 (12.5%) had depression. The clinical findings from this large observational study indicate that patients with depression showed an inverse correlation with T2MI compared to patients without depression. It was observed that patients with depression had lower odds of all-cause mortality, cardiogenic shock, cardiac arrest, and stroke. Additionally, the study found that patients with depression had lower hospitalization costs with a similar mean length of stay compared to patients without depression. Previous studies have shown that depression is a significant risk factor for the development of CAD. Still, there is limited evidence for the impact of depression on T2MI.
This study also identified significant variations in the prevalence of depression among T2MI patients based on gender, with potential explanations including disparities in biological factors such as hormones, as well as psychosocial factors[19]. Another study indicated that female cohorts with CHD were at a 1.77-fold higher risk of experiencing depression compared to male cohorts[20]. Furthermore, we observed notable differences in the prevalence of depression in T2MI admissions based on race and region, with higher rates in white patients and increased prevalence in urban teaching hospitals, possibly reflecting variances in socioeconomic and sociocultural characteristics, as seen in other studies[21].
The presence of major depressive disorder has been associated with increased susceptibility to CAD, which raises the risk of illness and death despite advancements in medical and interventional treatments[3,9,14,15,18,22]. The precise mechanisms by which depression contributes to a heightened risk of CAD are not entirely understood[11,12]. However, several potential causes of CAD in individuals with depression have been suggested, including heightened platelet aggregation[23,24], increased levels of inflammatory markers, elevated catecholamine levels, alterations in cortisol levels, heightened sympathetic tone, potential variability in heart rate, sedentary lifestyle, and non-adherence to prevention and treatment of risk factors. A meta-analysis by Barth et al[16] and Nicholson et al[11] disclosed an increased probability of CAD in people with depression, as well as a twofold rise in mortality over two years. However, our study discovered that the occurrence of depression among admissions for T2MI is roughly 12.5%. Additionally, we noted that patients with depression have a higher prevalence of obesity (21.3% vs 17.9%) and hyperlipidemia (56.5% vs 48.9%), likely due to changes in lifestyle and diet.
Patients with depression were at a two to fourfold increased risk of developing CAD at some point in their lifetime[25,26]. Several other epidemiological studies have emphasized the higher incidence of depression in patients with ischemic heart diseases, particularly within the first one to two years[27,28]. While there have been no studies in the literature examining the impact of depression on T2MI and outcomes, our study revealed decreased risks of all-cause mortality, cardiogenic shock, and cardiac arrest during T2MI hospitalization in patients with depression. This contrasts previous studies on T1MI and depression, as several meta-analyses have previously indicated a 10%-25% increased risk of all-cause mortality and cardiovascular mortality in patients with T1MI and depression[29,30]. The exact mechanism of how there is a protective effect with depression and T2MI is unknown. However, Serebruany et al[31] demonstrated that patients who are on anti-depressants have a favorable impact on the outcomes, possibly due to changes in serotonin activity, which we couldn’t access in our study, which might impact the outcomes.
Several theories have been proposed in the literature regarding the potential link between depression, atherosclerosis, and stroke. One theory involves neuroendocrine dysfunction resulting from the dysregulation of the hypothalamic-pituitary-adrenocortical axis, platelet aggregation dysfunction[32], and immunological/inflammatory effects[33], which may elevate the risk of stroke. In recent years, studies have indicated that inflammatory cytokines, such as interleukins (IL-1, IL-2, IL-6), C-reactive protein, tumor necrosis factor α, IL-1β, and P-selectin, play a significant role in the development and rupture of atherosclerosis plaques, which are major contributors to CAD and stroke[34]. Our study has suggested a paradoxical lower risk of stroke in patients admitted with depression and T2MI. This could be attributed to variations in neurotransmitters or pathways in T2MI patients. Additionally, selective serotonin reuptake inhibitor medication may have protective effects against stroke, as indicated in previous research, beyond its antidepressant effects[35]. However, some other studies found a positive association between anti-depressants and stroke risk[36].
In this research, the unexpected discovery that depression may be linked to improved clinical outcomes in a cardiac context could be influenced by various factors. Patients with a depression diagnosis might receive careful monitoring and treatment due to perceived higher risks, leading to early identification and management of complications. Furthermore, the unique psychological traits of these individuals could affect their perception of pain and reporting, potentially influencing the nature and timing of the care they receive. Additionally, there is a possibility that certain antidepressant medications might unintentionally have beneficial effects on the heart, as suggested by studies exploring the cardiovascular impacts of psychiatric therapies. This surprising association emphasizes the complexity of mental health’s influence on cardiovascular health outcomes. It underscores the need for further research to fully understand the underlying mechanisms and potential clinical implications for patients with depression or other mental health disorders in the context of T2MI.
Future directions
This study examining the link between depression and T2MI and associated subsequent MACE provided preliminary insights and paved the way for future prospective investigations. Its strength lies in analyzing a large dataset with more generalizable findings, minimized selection bias and controlled confounders in comprehensive multivariable analysis ensuring the reliability of its findings. Additionally, future longitudinal research could address limitations by exploring stages and severity of depression, medication adherence and social influences to enhance our knowledge of the link between depression and T2MI outcomes.
Limitations
Our study has several limitations. Firstly, we focused our analysis on T2MI hospitalizations using ICD-10 codes in adults aged 18 and above, which helped minimize selection bias by narrowing down the study population. We utilized the National Inpatient Sample for 2019 and identified cohorts admitted with T2MI using ICD-10 codes. However, this approach may introduce the possibility of misclassification, particularly regarding height and weight measurements. Nonetheless, this potential misclassification should be consistent among survivors and non-survivors, thus not significantly affecting the interpretation of the results. We did not consider different stages of depression, which could potentially impact the population in various ways. Furthermore, it is crucial to have access to more comprehensive data concerning the medication status, social determinants, and adherence of the cohorts. These variables have the potential to serve as confounding factors, especially about mortality within the demographic afflicted by depression. However, it is essential to note that the substantial sample size of our study enhances its statistical robustness, helping to mitigate the limitations above.
CONCLUSION
This study revealed a significantly lower risk of T2MI related admissions in patients with depression compared to patients without depression and lower odds of adverse in-hospital outcomes such as all-cause mortality, cardiogenic shock, cardiac arrest, and stroke in T2MI patients with depression. It’s important to consider potential confounding variables that could influence the study outcomes, such as medication usage, psychosocial factors, and the different stages of depression, all of which play a crucial role in the progression of the disease and the outcomes. Previous studies have not explored the impact of depression on T2MI outcomes, and further prospective studies are needed to evaluate the influence of depression on various in-hospital outcomes across different stages of depression. Additionally, it is essential to investigate the effects of medication, duration, and serotonin levels on T2MI.
Footnotes
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Cardiac and cardiovascular systems
Country of origin: United States
Peer-review report’s classification
Scientific Quality: Grade C
Novelty: Grade C
Creativity or Innovation: Grade B
Scientific Significance: Grade C
P-Reviewer: Rwegerera GM S-Editor: Wang JJ L-Editor: A P-Editor: Yuan YY
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Eur Heart J. 2021;42:1289-1367.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 2569][Cited by in F6Publishing: 2803][Article Influence: 934.3][Reference Citation Analysis (0)]
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018;392:1736-1788.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 4577][Cited by in F6Publishing: 4223][Article Influence: 703.8][Reference Citation Analysis (1)]
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018).Circulation. 2018;138:e618-e651.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1019][Cited by in F6Publishing: 1787][Article Influence: 357.4][Reference Citation Analysis (0)]
Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Diamond GA, Fesmire FM, Geraci SA, Gersh BJ, Larsen GC, Kaul S, McKay CR, Philippides GJ, Weintraub WS. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents.J Am Coll Cardiol. 2012;60:2427-2463.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 278][Cited by in F6Publishing: 263][Article Influence: 21.9][Reference Citation Analysis (0)]
Smolderen KG, Buchanan DM, Gosch K, Whooley M, Chan PS, Vaccarino V, Parashar S, Shah AJ, Ho PM, Spertus JA. Depression Treatment and 1-Year Mortality After Acute Myocardial Infarction: Insights From the TRIUMPH Registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status).Circulation. 2017;135:1681-1689.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 67][Cited by in F6Publishing: 82][Article Influence: 11.7][Reference Citation Analysis (0)]
Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, Blackett KN, Sitthi-amorn C, Sato H, Yusuf S; INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study.Lancet. 2004;364:953-962.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1484][Cited by in F6Publishing: 1406][Article Influence: 70.3][Reference Citation Analysis (0)]
van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, van den Brink RH, van den Berg MP. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis.Psychosom Med. 2004;66:814-822.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 718][Cited by in F6Publishing: 726][Article Influence: 36.3][Reference Citation Analysis (0)]
Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, Freedland KE, Jaffe AS, Leifheit-Limson EC, Sheps DS, Vaccarino V, Wulsin L; American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association.Circulation. 2014;129:1350-1369.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 685][Cited by in F6Publishing: 770][Article Influence: 77.0][Reference Citation Analysis (0)]
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.Circulation. 2010;121:948-954.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 1137][Cited by in F6Publishing: 1176][Article Influence: 84.0][Reference Citation Analysis (1)]
Eaton WWFJ, Armenian HK.
The consequences of psychopathology in the Baltimore Epidemiologic Catchment Area Follow-up. In: Medical and Psychiatric Co-Morbidity over the Lifespan. Washington: American Psychiatric Publishing, 2006: 21-38.
[PubMed] [DOI][Cited in This Article: ]
Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, Doyle F, Freedland KE, Grace SL, Hosseini SH, Lane DA, Pilote L, Parakh K, Rafanelli C, Sato H, Steeds RP, Welin C, de Jonge P. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis.Br J Psychiatry. 2013;203:90-102.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 140][Cited by in F6Publishing: 135][Article Influence: 12.3][Reference Citation Analysis (0)]
Serebruany VL, Suckow RF, Cooper TB, O'Connor CM, Malinin AI, Krishnan KR, van Zyl LT, Lekht V, Glassman AH; Sertraline Antidepressant Heart Attack Randomized Trial. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression.Am J Psychiatry. 2005;162:1165-1170.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 57][Cited by in F6Publishing: 62][Article Influence: 3.3][Reference Citation Analysis (0)]
Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.J Am Coll Cardiol. 2000;35:1535-1542.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 264][Cited by in F6Publishing: 283][Article Influence: 11.8][Reference Citation Analysis (0)]
Alqdwah-Fattouh R, Rodríguez-Martín S, Barreira-Hernández D, Izquierdo-Esteban L, Gil M, González-Bermejo D, Fernández-Antón E, Rodríguez-Miguel A, García-Lledó A, Bolúmar F, de Abajo FJ. Selective Serotonin Reuptake Inhibitors and Risk of Noncardioembolic Ischemic Stroke: A Nested Case-Control Study.Stroke. 2022;53:1560-1569.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]